Lorlatinib/Lorlatinib: Medicare Prices and Medication Guide

Lorlatinib Lorlatinib is a targeted drug designed to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body. It provides new treatment options for NSCLC patients by inhibiting the function of abnormal proteins, thereby preventing the reproduction and spread of cancer cells.

Lorlatinib is already on the market in China and has been included in the reimbursement scope of Class B medical insurance, reducing the financial burden for eligible patients. The drug is taken in the form of oral tablets and is usually recommended once a day, before or after a meal, but patients should try to take it at the same time every day to ensure a stable concentration of the drug in the body.

Lorlatinib, a third-generation anaplastic lymphoma kinase inhibitor (ALK), has significant anti-tumor activity in patients who have previously received treatment for ALK-positive NSCLC. When taking lorlatinib, patients should follow their doctor's advice and do not overdose or reduce the dose, nor take it more often than the doctor recommends. If vomiting occurs after taking the medication, there is no need to take additional doses, just continue to follow the original medication plan. At the same time, patients should swallow the tablets whole and avoid cutting, chewing or crushing to ensure the integrity and effectiveness of the medicine.

In the domestic market, the common specifications of lorlatinib are25mg 90 tablets and 100mg 30 tablets. The price of each box of medicine is about 10,000 yuan, but the specific price may vary depending on the region and sales channel. In addition, due to different medical insurance reimbursement ratios in different regions, the actual fees paid by patients will also vary. Therefore, it is recommended that patients consult local medical insurance bureaus or hospitals and other relevant institutions to learn about specific reimbursement policies and price information before purchasing drugs.